+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
511523 VEERHEALTH

Veerhealth Care Share Price

 
Stock touched ten year high

 

Veerhealth Care live price: ₹33.9. It opened at ₹34 vs previous close ₹34; intraday high/low: ₹34/₹34. The 50 & 200 DMA stand at ₹26.53/₹21.72.

Veerhealth Care Performance

  • Today's Low
  • ₹34
  • Today's High
  • ₹34
  • 52 Week Low
  • ₹17
  • 52 Week High
  • ₹34
  • Open Price₹34
  • Previous Close₹34
  • Volume64,016
  • 50 DMA₹26.53
  • 100 DMA₹23.87
  • 200 DMA₹21.72

Veerhealth Care Chart

Investment Returns

  • Over 1 Month + 39.79%
  • Over 3 Month + 62.75%
  • Over 6 Month + 78.8%
  • Over 1 Year + 70.27%

Smart Investing Starts Here Start SIP with Veerhealth Care for Steady Growth!

Invest Now

Veerhealth Care Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 124.6
  • PEG Ratio
  • 3.2
  • Market Cap Cr
  • 68
  • P/B Ratio
  • 3
  • Average True Range
  • 0.92
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.22
  • RSI
  • 96.37
  • MFI
  • 100

Veerhealth Care Financials

Veerhealth Care Technicals

EMA & SMA

Current Price
₹33.90
-0.03 (-0.09%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹30.00
  • 50 Day
  • ₹26.50
  • 100 Day
  • ₹23.90
  • 200 Day
  • ₹21.70

Resistance and Support

33.94 Pivot Speed
  • R3 34.05
  • R2 34.01
  • R1 33.98
  • S1 33.91
  • S2 33.87
  • S3 33.84

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Veerhealth Care has an operating revenue of Rs. 32.48 Cr. on a trailing 12-month basis. An annual revenue growth of 86% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 16%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 31% and 60% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 42% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 22 which is a POOR score indicating inconsistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Veerhealth Care Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-30 Audited Results & Dividend
2026-03-28 Preferential Issue of shares Inter alia, to consider 1. Proposal for raising of funds by way of issue of one or more instruments including equity shares/convertible securities either by way of Preferential Issue or any other mode issue in the ratio of 1:1 of Rs. 10/-.
2026-02-14 Quarterly Results
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results & A.G.M.
Date Purpose Remarks
2023-09-22 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Veerhealth Care Shareholding Pattern

31.5%
54.27%
14.23%

Veerhealth Care FAQs

Veerhealth Care share price is ₹33 As on 07 July, 2026 | 18:15

The Market Cap of Veerhealth Care is ₹67.8 Cr As on 07 July, 2026 | 18:15

The P/E ratio of Veerhealth Care is 124.6 As on 07 July, 2026 | 18:15

The PB ratio of Veerhealth Care is 3 As on 07 July, 2026 | 18:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23